论文部分内容阅读
目的探讨前列地尔针联合胰激肽原酶针治疗糖尿病肾病的临床效果。方法收集2010年6月—2016年1月诊疗的150例糖尿病肾病患者的临床资料,根据入院顺序随机将150例患者分为观察组(n=75)及对照组(n=75),对照组患者在常规控制血糖基础上加用胰激肽原酶针治疗,观察组患者采用胰激肽原酶针联合前列地尔针治疗方案,对比观察两组患者治疗前后血清肌酐(SCr)、血尿素氮(BUN)、24h尿道白定量(24h UPR)等指标变化,计算治疗有效率,并行统计学对比。结果经积极治疗,观察组患者SCr(109.5±22.5)umol/L,BUN(10.1±1.4)mmol/L,24h UPR(0.18±0.1)g,各项指标均优于对照组,差异均存在统计学意义(P<0.05)。结论在常规控制血糖基础上采用前列地尔针联合胰激肽原酶针治疗糖尿病肾病效果确切,能有效改善患者肾滤过功能,减少尿蛋白含量,不良反应少,值得临床推广应用。
Objective To investigate the clinical effect of alprostadil combined with pancreatic kallikrein in the treatment of diabetic nephropathy. Methods The clinical data of 150 patients with diabetic nephropathy diagnosed and treated from June 2010 to January 2016 were collected and randomly divided into observation group (n = 75) and control group (n = 75) according to the order of admission. The control group Patients with conventional control of blood glucose plus pancreatic kallikrein acupuncture treatment, observation group patients with pancreatic kallikrein combined with alprostadil acupuncture treatment regimen, the two groups were observed before and after treatment serum creatinine (SCr), blood urea Nitrogen (BUN), 24h urethral white quantitative (24h UPR) and other indicators change, calculate the treatment efficiency, parallel statistical comparison. Results After active treatment, SCr (109.5 ± 22.5) umol / L, BUN (10.1 ± 1.4) mmol / L and UPR (0.18 ± 0.1) g in observation group were higher than those in control group Significance (P <0.05). Conclusion The conventional control of blood glucose based on the use of alprostadil combined with pancreatic kallikrein treatment of diabetic nephropathy needle exactly, can effectively improve renal filtration function, reduce urinary protein content, fewer adverse reactions, it is worthy of clinical application.